DDInter840 DDInter1676
A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Granisetron {u} (Compound) resembles {v} (Compound) Hyoscyamine
Granisetron {u} (Compound) resembles {v} (Compound) Atropine
Granisetron {u} (Compound) binds {v} (Gene) CYP3A4
Granisetron {u} (Compound) upregulates {v} (Gene) CASP10
Granisetron {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin 3 Receptor Antagonists
Granisetron {u} (Compound) downregulates {v} (Gene) HSPA1A
Granisetron {u} (Compound) causes {v} (Side Effect) Hepatic enzyme increased
Granisetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Granisetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Granisetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Granisetron (Compound) resembles Hyoscyamine (Compound)
Granisetron (Compound) resembles Atropine (Compound)
Granisetron (Compound) binds CYP3A4 (Gene)
Granisetron (Compound) upregulates CASP10 (Gene)
Granisetron (Compound) is included by Serotonin 3 Receptor Antagonists (Pharmacologic Class)
Granisetron (Compound) downregulates HSPA1A (Gene)
Granisetron (Compound) causes Hepatic enzyme increased (Side Effect)
Granisetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Granisetron may cause a minor interaction that can limit clinical effects when taken with Modafinil
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib